ASH 2016 - Multiple Myeloma
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
In this analysis, researchers evaluate whether daratumumab can further reduce minimal residual disease when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.
Meta-Analysis to Compare Efficacy of Treatment Regimens for Relapsed/Refractory Multiple Myeloma Patients
Phase II Study of Lenalidomide, Subcutaneous Bortezomib, and Dexamethasone (RsqVD) in Newly Diagnosed Multiple Myeloma
In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.
Budget Impact Analysis of Elotuzumab in Combination with Lenalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Payers have expressed concern about the rising costs of combination therapies in multiple myeloma. In an effort to address these potential concerns, a budget impact model was developed to estimate the 3-year costs of adding elotuzumab in combination with lenalidomide and dexamethasone to a health plan’s formulary.
A New Risk Stratification Tool to Estimate Survival in Patients with Multiple Myeloma After First Relapse
Risk stratification tools are used to estimate survival expectations and help to guide treatment decisions after first relapse in multiple myeloma. European researchers have developed a new stratification tool consisting of 4 distinct dimensions that are used to characterize risk of survival.
Pembrolizumab in Combination with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Immunotherapy is being studied as a potential treatment approach in a variety of hematologic malignancies. Here, researchers present the findings of a phase 2 trial evaluating pembrolizumab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.
Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.
PREAMBLE (Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation) is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with one line of prior therapy.
Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma
Novel triplet combinations are being evaluated in both the newly diagnosed and relapsed/refractory settings in multiple myeloma. This study evaluates the efficacy and safety of ixazomib, pomalidomide, and dexamethasone combination therapy in a heavily pretreated, high-risk patient population.
Real-World Trends in Treatment Use, Healthcare Costs, and Overall Survival Among Patients with Multiple Myeloma
Payers seek to understand the value of myeloma treatment options by assessing outcomes relative to cost. This claims-based analysis assesses trends in novel therapy use, total healthcare costs, and survival outcomes among newly diagnosed multiple myeloma patients in the United States since 2000.
Page 1 of 2
Results 1 - 10 of 19
Results 1 - 10 of 19